When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.
Global Industrial (GIC)
Consensus Price Target: $40 (3.4% implied return)
Formerly known as Systemax, Global Industrial (NYSE:GIC) distributes industrial and commercial products to businesses and institutions.
Why Are We Wary of GIC?
- Muted 3.3% annual revenue growth over the last two years shows its demand lagged behind its industrials peers
- Flat earnings per share over the last two years underperformed the sector average
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
At $38.69 per share, Global Industrial trades at 19.1x forward P/E. Dive into our free research report to see why there are better opportunities than GIC.
Ducommun (DCO)
Consensus Price Target: $212 (11.7% implied return)
California’s oldest company, Ducommun (NYSE:DCO) is a provider of engineering and manufacturing services for high-performance products primarily within the aerospace and defense industries.
Why Are We Hesitant About DCO?
- Backlog has dropped by 16% on average over the past two years, suggesting it’s losing orders as competition picks up
- Day-to-day expenses have swelled relative to revenue over the last five years as its operating margin fell by 8.9 percentage points
- Underwhelming 2.6% return on capital reflects management’s difficulties in finding profitable growth opportunities
Ducommun is trading at $189.86 per share, or 40.9x forward P/E. Check out our free in-depth research report to learn more about why DCO doesn’t pass our bar.
Bruker (BRKR)
Consensus Price Target: $58.75 (-1.8% implied return)
With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels.
Why Does BRKR Worry Us?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Performance over the past five years shows its incremental sales were less profitable as its earnings per share were flat
- Diminishing returns on capital suggest its earlier profit pools are drying up
Bruker’s stock price of $59.80 implies a valuation ratio of 25.9x forward P/E. To fully understand why you should be careful with BRKR, check out our full research report (it’s free).
Stocks We Like More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.